“Pay to Delay” Pharmaceutical Settlements: A Consumer Perspective
There has been increasing litigation, particularly within the last decade amongst consumers, the FTC, branded drug manufacturers, and generic drug manufacturers, since the 1984 enactment of Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act. This controversy presents a unique dilemma to consumers, who would like to think that the … Continued